Skip to main content

Advertisement

Log in

The research mission in myeloma

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bergsagel PL . A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy. Leukemia 2008; 22: 673–675.

    Article  CAS  Google Scholar 

  2. Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008; 22: 850–855.

    Article  CAS  Google Scholar 

  3. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern cooperative oncology group. Blood 2007; 110: 74.

    Article  Google Scholar 

  4. San Miguel JF, Schlag R, Khuageva N, Shpilberg O, Dimopoulos M, Kropff M et al. MMY-3002: a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood 2007; 110: 76.

    Google Scholar 

  5. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

    Article  CAS  Google Scholar 

  6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al., Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142.

    Article  CAS  Google Scholar 

  7. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al., Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.

    Article  CAS  Google Scholar 

  8. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901.

    Article  CAS  Google Scholar 

  9. Jawed I, Lee CM, Tward JD, Macdonald OK, Martincic D, Vudarla N et al. Survival outcomes for multiple myeloma over three decades: a surveillance, epidemiology, and end results (SEER) analysis. J Clin Oncol 2007; 25 (18s): 8019.

    Google Scholar 

  10. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P G Richardson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richardson, P., San-Miguel, J., Lonial, S. et al. The research mission in myeloma. Leukemia 23, 422–423 (2009). https://doi.org/10.1038/leu.2008.209

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.209

  • Springer Nature Limited

This article is cited by

Navigation